TIGIT and neoplasm: Cell-cell interaction showed that the interaction between TIGIT on MCL cells and its ligand CD155 on CD16+ monocytes significantly increased after relapse, which might attenuate the ability of myeloid cells to present tumor antigens and lead to weaker antitumor immune surveillance.